Disease-free survival in patients with non-metastatic breast cancer

Abstract

Introduction: Breast cancer is the second most common malignancy in the world and the one with highest incidence in the female population; it is also a major cause of death from cancer among women. Objective: To analyze the disease-free survival (DFS) at 5 years and prognostic factors in women with non-metastatic invasive breast cancer treated at a referral center for cancer care located in a medium-sized city in the Southeast of Brazil. Method: Patients diagnosed with the disease between 2003 and 2005 and identified through the institution's cancer hospital records were analyzed. The follow--up of cases was carried out through hospital records, and complemented by search in the database of the Mortality Information System (SIM) as well as telephone contact. The variables analyzed were distributed in the following blocks: socio-demographic data, tumor-related characteristics, and treatment-related characteristics. Survival functions were calculated using the Kaplan-Meier method and the prognostic factors were analyzed based on Cox proportional hazard model. Results:The study showed a DFS at 5 years of 72% (95CI 67.6-75.9). The main variables independently associated with DFS were lymph node involvement, use of hormone therapy, and education level. Conclusion: This study reinforces the importance of early diagnosis for DFS, pointing to the role of social aspects in this regard. The relevance of this research in the country is also highlighted, given the scarcity of studies on DFS in the Brazilian population.

Undetected αKlotho in serum is associated with the most aggressive phenotype of breast cancer

“…Klotho is a protein that is considered to be closely tied to lifespan; therefore, investigating the overall lifespan of patients was of interest. There was no difference in overall patient survival depending on αKlotho status, but results similar to those encountered in the literature were obtained when considering certain variables, such as molecular subtype, tumor grade, lymph node status and TNM classification (78)(79)(80)(81). The present results demonstrated that patients with tumors that had certain histopathological variables considered important for overall survival had undetected αKlotho.…”

Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon

“…Overall 5-year disease-free rates: ipsilateral breast tumour recurrence,97.4%; LR,95.6%; DM: 92.9%, and cancer–specific death:96.3%. Significant difference in survival between subtypes (of invasive breast cancer) for LR, DM and breast cancer–specific death Diniz et al 2016, Brazil (South America) [ 11 ] Disease-free survival in patients with NMBC Three-year retrospective single-centre study:563 cases Disease recurrence noted in 129 cases:17.8% LR; 54.3% DM and 27.9% died. Disease free survival at 5 years:72% Budakoglu et al 2014, Turkey (Eurasia) [ 12 ] Outcome of triple negative NMBC patients Eleven-year multi-center retrospective study:561 cases Ratio of triple-negative breast cancer:12%.…”

Registros Hospitalares de Câncer de Mato Grosso: análise da completitude e da consistência

“…O estudo dessa variável permite ainda realizar comparações, como busca precoce por diagnóstico, adesão ao tratamento, avaliação de sobrevida e recidiva da doença, entre outras. Várias pesquisas foram realizadas na busca de analisar os fatores associados à escolaridade e ao câncer de mama [24][25][26] . Esses estudos apontam que, talvez por causa do estilo de vida e comportamento, o resultado das mulheres com escolaridade maior foi melhor que das demais.…”

“…Pesquisas realizadas com dados do RHC do Brasil e de Minas Gerais observaram grau de completitude "regular" para a variável estado da doença ao final do primeiro tratamento. Vários estudos foram realizados 25,[38][39][40][41][42] com o objetivo de analisar diferentes tipos de tratamento. Para comparar os procedimentos realizados na assistência oncológica, informações acerca do tratamento precisam estar registradas no prontuário.…”